ClinicalTrials.gg
RecruitingNCT07455994DYSDIABUpdated Mar 6, 2026

Dysautonomia in Children With Type 1 Diabetes

An interventional study of Neurocoach® and Sudoscan® in Dysautonomia in Children With Type 1 Diabetes and Healthy Volunteer, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 1 Year to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.

Planned enrollment
150th of 242
100 · median 187
Started
2025
with 10 others
No phase
100 of 352
22 open now
Primary completion
2026-12
later than 23 of 51 live
Registered
345th of 352
by date

Among the 352 studies in Diabetes Mellitus with a site in France, this one is the 150th largest by planned enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2025, is one of 100 with no phase, reaches primary completion later than 23 of the 51 other live ones, and was the 345th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 352 studies in Diabetes Mellitus with a site in France, or all of them as a file.
02

Study summary

Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their sympathetic and parasympathetic balance. These conditions can alter the physiological autonomic balance, sometimes with positive consequences on the FC-breathing control and blood pressure adjustment, depending on the individual's position and the status of blood volume, but sometimes with deleterious effects, such as poor regulation of sinus cardiac activity and respiration rate.

Cardiovascular autonomic neuropathy is a major complication of type 1 diabetes. Several studies have described autonomic dysfunction in patients with type 1 diabetes, but these data are derived from cohorts of adults and adolescents or short ECG recordings at rest. Moreover, there are often confounding factors such as sedentary/physical activity, overweight, exposure to post-pubertal hormonal peaks, toxic drugs, or cardiac therapy.

These factors don't greatly influence children's autonomic physiological maturation, whereas diabetes can sometimes exist for several years. In this population, the search for cardiac dysautonomia is entirely appropriate.

Read the detailed description

The objective of this study is to evaluate the indices of heart rate variability (from a 24-hour Holter and a cutaneous conductance) in children with type 1 diabetes compared with healthy controls matched to sex and age, and to determine whether the occurrence of cardiac dysautonomia is correlated with the duration of diabetes progression.

03

Conditions studied

  • Dysautonomia in Children With Type 1 Diabetes
  • Healthy Volunteer

Keywords

  • diabetes
  • dysautonomia
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents affiliates or entitled to the French Social Security Fund
  • Children\<18 years with type 1 diabetes followed in consultation at the University Hospital of Saint-Etienne
  • Children under 18 years of age, matched for age (±6 months) and sex, without diabetes or dysautonomia (control group), who have not undergone anesthesia within the 2 months preceding the recording and are not receiving any cardiac (beta-blocker) or antiarrhythmic treatment.

Exclusion criteria

Exclusion Criteria:

  • Children with a diagnosis of diabetes of less than 5 years' duration at the time of inclusion.
  • Children with diseases that affect the central nervous system or brainstem
  • Children suffering from a serious pathology of the cardiorespiratory system or during cardiac treatment (cardiopathies, rhythmic disorders)
  • Foreign parents or children who don't speak French.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Diabetic subjects

    50 pediatric diabetic subjects with at least 5 years of type 1 diabetes).

    Diagnostic Test: Neurocoach® and Sudoscan®

  • Active comparator
    healthy group

    50 healthy subjects matched for age and sex

    Diagnostic Test: Neurocoach® and Sudoscan®

Interventions

  • Diagnostic testNeurocoach® and Sudoscan®

    The objective of this study is to evaluate the indices of heart rate variability (from a 24-hour Holter and a cutaneous conductance) in children with type 1 diabetes compared with healthy controls matched to sex and age, and to determine whether the occurrence of cardiac dysautonomia is correlated with the duration of diabetes progression.

06

What researchers measure

Primary outcomes

  1. HF ECG index value

    HF index value (ms2/Hz) of high-frequency heart rate variability in the frequency domain

    Time frame: During 24 hours

Secondary outcomes

  1. Sympathetic and parasympathetic indices of heart rate variability

    Secondary endpoints: Sympathetic and parasympathetic indices of heart rate variability in the linear frequency domains (Ptot, VLF, LF, LF/HF ratio), time domains (SDNN, pNN30, pNN50, rMSSD), and nonlinear domains (Approximate entropy, SD1, SD2, chaos). Quantifying the Mean ESC value (µS) of the hands and feet.

    Time frame: During 24 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartActual
Dec 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07455994
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Dec 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Hugues PATURAL, MD PhD
Contact
hugues.patural@chu-st-etienne.fr
(0)4 77 82 82 42 ext. +33
Meryem BRITAL, CDP
Contact
meryem.brital@chu-st-etienne.fr
(0)4 77 42 06 83 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion